The Public Authority for Health Care (PAHC) and Janssen International, a subsidiary of Johnson & Johnson, recently convened to discuss potential areas of collaboration in the health sector. The meeting between Ahmed El-Sobky, President of PAHC and General Supervisor of the Universal Health Insurance and Decent Life Projects of the Ministry of Health, and Sanae Mousannif, Head of Market Access and Public Affairs for Morocco, Tunisia, and French-speaking Africa at Janssen International, explored new avenues of cooperation between the two entities.
During the meeting, particular focus was given to the fields of blood diseases, immunology, and health economics. The participants also reviewed the outcomes of a previously signed cooperation protocol, which aimed at enhancing PAHC’s capabilities in diagnosing and treating blood and immune diseases, as well as improving patient care and fostering innovative health solutions.
El-Sobky highlighted the significance of bolstering partnerships with the private sector to achieve the highest standards of healthcare. He stated, “We are preparing to announce the establishment of the first regional center of excellence for the treatment of blood diseases and cancers in collaboration with Janssen International. This groundbreaking medical facility will revolutionize the treatment journey for patients, providing integrated and comprehensive care and aligning with PAHC’s vision of patient-centered care and meeting their healthcare needs.”
Mousannif expressed her satisfaction with the collaboration with PAHC, commending its forward-thinking approach. She remarked, “Based on the cooperation protocol with PAHC, we have decided to increase Janssen’s investments in Egypt and expand the company’s activities. This collaboration reflects Janssen’s strategy and its commitment to forging partnerships to achieve the highest levels of healthcare for all, which remains our primary focus when engaging with the Egyptian health sector.”
